Johnson & Johnson
JNJleaderJohnson & Johnson is a global healthcare company operating in pharmaceuticals and medical devices. Following the spin-off of its consumer health division as Kenvue, it focuses on innovative medicine and MedTech.
ผลิตภัณฑ์และรายได้
สัดส่วนรายได้ผลิตภัณฑ์
โครงสร้างรายได้ ($85.2B)
ข้อมูลคงที่ (กำลังโหลดข้อมูลการเงิน…)
โครงสร้างส่วนงานและลูกค้าหลัก
รายละเอียดผลิตภัณฑ์
Pharmaceutical products including immunology, oncology, and neuroscience therapeutics
Surgical instruments, robotics, and interventional solutions
Joint reconstruction, spine, and sports medicine implants
ความสัมพันธ์ซัพพลายเชน
บริบทมหภาคและตลาด
메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요
미국 헬스케어 지출 (2026E)
AI 진단 정확도 개선
UNH 의료손해율
약가 협상 대상 의약품
ตัวเร่งปฏิกิริยาที่จะมาถึง
สัญญาณสถาบัน
| สถาบัน | การดำเนินการ | มูลค่า | ไตรมาส | วันยื่นรายงาน |
|---|---|---|---|---|
| BlackRock | accumulating | $923M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $384M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $358M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $25M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $50M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $948M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $431M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $10.9B | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $7.7B | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $714M | 2024.06 | 2024-08-13↑ |
| BlackRock | accumulating | $1.2B | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $509M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $870M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $27M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $2.5B | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $137M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $41M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $515M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $80M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $17M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $531M | 2024.06 | 2024-08-13↑ |
| Vanguard Group | accumulating | $1.1B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $222M | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $44.8B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $2.8B | 2025.12 | 2026-01-29↑ |
| Vanguard Group | accumulating | $828M | 2025.12 | 2026-01-29↑ |
| Vanguard Group | reducing | $11K | 2025.12 | 2026-01-29↓ |
| Vanguard Group | accumulating | $4M | 2025.12 | 2026-01-29↑ |
| State Street | accumulating | $27.7B | 2025.12 | 2026-02-13↑ |
| Wellington Management | accumulating | $4.7B | 2025.12 | 2026-02-17↑ |
| Wellington Management | accumulating | $36M | 2025.12 | 2026-02-17↑ |
| Wellington Management | reducing | $6M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $2M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $2M | 2025.12 | 2026-02-17↓ |
| Wellington Management | reducing | $14M | 2025.12 | 2026-02-17↓ |
| Wellington Management | accumulating | $53M | 2025.12 | 2026-02-17↑ |
| Wellington Management | accumulating | $27M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $2.2B | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | reducing | $509K | 2025.12 | 2026-02-17↓ |
| FMR (Fidelity) | accumulating | $19M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $1.3B | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $43M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $386M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | accumulating | $14M | 2025.12 | 2026-02-17↑ |
ข่าวล่าสุด
การวิเคราะห์ AI
คลิก "รับการวิเคราะห์ AI" เพื่อรับการวิเคราะห์ซัพพลายเชนของ Johnson & Johnson
ข้อมูลบริษัท
ภาพรวมภาคส่วน — 헬스케어
ข่าวภาคส่วน메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요
미국 헬스케어 지출 (2026E)
AI 진단 정확도 개선
UNH 의료손해율
약가 협상 대상 의약품
ธีมหลัก
- •CMS 메디케어 어드밴티지 수가 인하 → 보험사 마진 압박
- •AI 영상진단·병리학 도입 가속 — Tempus, Veracyte 수혜
- •GLP-1 보험 적용 확대 논의 → UNH·CVS 비용 증가 리스크
ตัวเร่งปฏิกิริยาที่จะมาถึง
- ◆CMS 메디케어 최종 수가 발표 (2026.Q2)
- ◆UNH/HUM/CVS Q1 실적 (2026.04)